{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-23-000004","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.131743+00:00","generated_at":"2026-06-20T17:58:38.307113+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Moderna reports prelim 2022 COVID sales $18.4B; reiterates 2023 $5B min; RSV study accrues cases","bullets":["Prelim 2022 COVID vaccine sales ~$18.4B; R&D ~$3.3B; cash & investments >$18B.","2023 min COVID sales reiterated at ~$5B; R&D budget rises to ~$4.5B.","RSV vaccine (mRNA-1345) Phase 3 in older adults accrued enough cases for first interim efficacy analysis.","Personalized cancer vaccine mRNA-4157 + Keytruda reduced recurrence risk by 44% in melanoma; Phase 3 to start 2023.","Repurchased 23M shares for $3.3B in 2022; $2.8B remaining; acquired OriCiro Genomics."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-23-000004","json":"https://secwatch.observer/filing/0001682852-23-000004.json","markdown":"https://secwatch.observer/filing/0001682852-23-000004.md","text":"https://secwatch.observer/filing/0001682852-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285223000004/0001682852-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285223000004/mrna-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:58:38.307113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23c771bbe45751ead26e7ec98ea60647a6cf5dfd","claim":"Moderna, Inc. reported the fiscal year ended December 31, 2022 results: revenue approximately $18.4 billion.","evidence_excerpt":"COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285223000004/0001682852-23-000004-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"approximately $18.4 billion"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"8e856092996f8501bcd7c132c4d5240e4f650842","claim":"Moderna, Inc. reported 2023 results: revenue approximately $5.0 billion. Guidance reaffirmed.","evidence_excerpt":"Reiterating 2023 expected minimum COVID-19 vaccines sales of approximately $5.0 billion from confirmed Advance Purchase Agreements and 2022 contract deferrals","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285223000004/0001682852-23-000004-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Revenue","value":"approximately $5.0 billion"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}